Quotient - QTNT Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QTNT shares.
View QTNT analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price objectives for Quotient's stock. Their QTNT share price forecasts range from $1.50 to $3.00. On average, they predict the company's share price to reach $2.25 in the next twelve months. This suggests a possible upside of 1,451.7% from the stock's current price.
View analysts price targets for QTNT or view top-rated stocks among Wall Street analysts.

Quotient's stock was trading at $2.59 at the beginning of 2022. Since then, QTNT shares have decreased by 94.4% and is now trading at $0.1450.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our QTNT earnings forecast.

Quotient Limited (NASDAQ:QTNT) announced its quarterly earnings data on Tuesday, August, 9th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.09. The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.40 million.

Quotient updated its FY 2023 earnings guidance on Tuesday, September, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $39.00 million-$42.00 million, compared to the consensus revenue estimate of $40.87 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by a number of retail and institutional investors. Top institutional investors include Pura Vida Investments LLC (6.45%), JPMorgan Chase & Co. (3.38%), Walleye Capital LLC (2.91%), Walleye Capital LLC (2.91%), Millennium Management LLC (1.39%) and State Street Corp (0.48%). Insiders that own company stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Khoury Mohammad El, Manuel O Mendez, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Zubeen Shroff.
View institutional ownership trends.

Shares of QTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTNT stock can currently be purchased for approximately $0.15.

Quotient (NASDAQ:QTNT) has a market capitalization of $14.97 million and generates $38.51 million in revenue each year. The company earns $-125,130,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

The company employs 426 workers across the globe.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for the company is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at ir@quotientbd.com.